Business
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Three Additional Data Announcements Expected in 2023Completed Enrollment in Phase 2b VOYAGE Study of VK2809
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Conference call scheduled for 4:30 p.m. ET today\nThree Additional Data Announcements Expected in 2023Completed Enrollment in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in 2Q 2023Reported VK2735 Phase 1 Data Demonstrating Up to 6% Placebo-Adjusted Mean Weight Loss (7.8% from Baseline), Promising Safety and Tolerability Initiated Phase 1 Trial Evaluating Highly Differentiated Oral Formulation of VK2735; Results Expected in 2H 2023Completed Public Offering of Common Stock Raising Gross Proceeds of $287.5 MillionSAN DIEGO, April 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. (\"Viking\") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2023, and provided an update on its clinical pipeline and other corporate developments.\n\n \n \n \n \n \n \n\n \nHighlights from the Quarter Ended March 31, 2023, and Other Recent Events:\n\"The first quarter of 2023 was an exceptional period for Viking,\" stated Brian Lian, Ph.D., chief executive officer of Viking. \"Early in the quarter, we announced completion of enrollment in the Phase 2b VOYAGE study of our lead thyroid hormone receptor beta agonist VK2809 in patients with NASH and fibrosis, and we expect to report data for the primary endpoint of this study in the second quarter. Later in the quarter, we announced results from the first Phase 1 study of our dual incretin receptor agonist VK2735, demonstrating encouraging safety and tolerability, along with positive signs of clinical efficacy, and we expect to initiate a Phase 2 trial in patients with obesity around mid-year. In conjunction with the announcement of Phase 1 results for VK2735, we announced the initiation of a Phase 1 trial to evaluate an oral formulation of this important compound, and we continue to explore further expansion of our weight loss platform. Finally, at the end of the quarter we completed a successful public offering of common stock, strengthening our balance sheet and providing the resources to support the company through multiple clinical catalysts over the coming quarters.\"\nPipeline and Corporate Highlights\nOn Track to Announce Data from Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis in 2Q 2023. VK2809 is ...